Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 8/20 | 0.45 |
| ▸ | PPARA | Q07869 | 5/20 | 0.45 |
| ▸ | PPARG | P37231 | 2/20 | 0.43 |
| ▸ | MAOA | P21397 | 2/20 | 0.39 |
| ▸ | MAOB | P27338 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | AR | P10275 | 1/20 | 0.36 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5613728 | 0.85 | PPARD (0.65) | PPARDPPARAPPARGMAOAMAOB | |
| SCHEMBL5606352 | 0.85 | PPARD (0.47) | PPARDPPARAPPARGMAOAMAOB | |
| SCHEMBL5613384 | 0.81 | PPARD (0.55) | PPARDPPARAPPARGMAOAMAOB | |
| SCHEMBL5605559 | 0.78 | PPARD (0.60) | PPARDPPARAPPARGMAPT | |
| SCHEMBL5613508 | 0.77 | PPARA (0.59) | PPARDPPARAPPARGMAPT | |
| SCHEMBL14215718 | 0.76 | MAPT (0.45) | PPARDPPARAPPARGMAPTPTGDR2 | |
| SCHEMBL17431516 | 0.75 | PPARD (0.38) | PPARDPPARAMAOAMAOBMAPT | |
| SCHEMBL5606324 | 0.75 | MTNR1A (0.46) | PPARDPPARAPPARGTSHRKDM4E | |
| SCHEMBL5605647 | 0.75 | PPARD (0.44) | PPARDPPARAPPARGMAPTPTGDR2 | |
| SCHEMBL5613786 | 0.75 | PTGDR2 (0.43) | PPARDPPARAPPARGPTGDR2CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1749000-A2 | BICYCLIC, SUBSTITUTED TRIAZOLES AS MODULATORS OF PPAR AND METHODS OF THEIR PREPARATION | METABOLEX, INC. (US) | 2007-02-07 | — | — | EP | claimed |
| US-20060014785-A1 | BICYCLIC, SUBSTITUTED TRIAZOLES AS MODULATORS OF PPAR AND METHODS OF THEIR PREPARATION | METABOLEX, INC. (US) | 2006-01-19 | — | — | US | claimed |
| WO-2005115384-A2 | BICYCLIC, SUBSTITUTED TRIAZOLES AS MODULATORS OF PPAR AND METHODS OF THEIR PREPARATION | METABOLEX, INC. (US) | 2005-12-08 | — | — | WO | claimed |
| EP-1749000-A2 | BICYCLIC, SUBSTITUTED TRIAZOLES AS MODULATORS OF PPAR AND METHODS OF THEIR PREPARATION | METABOLEX, INC. (US) | 2007-02-07 | — | — | EP | disclosed |
| US-20060014785-A1 | BICYCLIC, SUBSTITUTED TRIAZOLES AS MODULATORS OF PPAR AND METHODS OF THEIR PREPARATION | METABOLEX, INC. (US) | 2006-01-19 | — | — | US | disclosed |
| WO-2005115384-A2 | BICYCLIC, SUBSTITUTED TRIAZOLES AS MODULATORS OF PPAR AND METHODS OF THEIR PREPARATION | METABOLEX, INC. (US) | 2005-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014785-A1 | BICYCLIC, SUBSTITUTED TRIAZOLES AS MODULATORS OF PPAR AND METHODS OF THEIR PREPARATION | PPARG, PPARD, GPR119 | PPARD 2/4885PPARA 4/4885PPARG 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.